Complete Genomics (NASDAQ: GNOM) is a life sciences company that has developed and commercialized a DNA sequencing platform for human genome sequencing and analysis. This solution combines the company's proprietary human genome sequencing technology with its informatics and data management software in an outsourced service model that provides its customers with finished variant reports and assemblies. Researchers send DNA samples to the company, which are sequenced at Complete Genomics' own commercial genome center in Mountain View, California. Sequencing is completed using the company's proprietary instruments and technology. Assembled sequences and variant reports are then delivered back to the researcher.
In February 2009, Complete Genomics announced that it had sequenced its first human genome and submitted the resulting variant data to the National Center for Biotechnology Information database. Then in November 2009, Complete Genomics published sequence data for three human genomes in the journal Science. By the end of 2009, Complete Genomics had sequenced 50 human genomes. The company has now significantly increased the throughput in its genome sequencing factory; it sequenced and analyzed 300 complete human genomes in Q3 2010.
In addition, Complete Genomics' customers are now publishing papers describing research completed using data from Complete Genomics. Examples include the Institute for Systems Biology's project to sequence a family of four and verify the gene responsible for Miller Syndrome, a rare craniofacial disorder and Genentech's work to sequence and compare a patient's primary lung tumor and adjacent normal tissue.
In September 2012 the Beijing Genomics Institute purchased Complete Genomics for $117M. The United States Committee on Foreign Investment in the United States cleared the purchase by December 2012.
Complete Genomics' proprietary human genome sequencing technology is optimized for the exclusive study of human DNA, providing assembled sequences and variation files. The technology relies on DNA nanoball sequencing. It is designed to use lower volumes and concentrations of reagents than existing systems. Additionally, Complete Genomics' proprietary instrumentation allows for greater numbers of base reads per image.
- Drmanac R, et al. (November 2009). "Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays". Science 327 (5961): 78–81. Bibcode:2010Sci...327...78D. doi:10.1126/science.1181498. PMID 19892942.
- Roach, et al.; Glusman, Gustavo; Smit, Arian F. A.; Huff, Chad D.; Hubley, Robert; Shannon, Paul T.; Rowen, Lee; Pant, Krishna P. et al. (30 April 2010). "Analysis of Genetic Inheritance in a Family Quartet by Whole-Genome Sequencing". Science 328 (5978): 636–639. Bibcode:2010Sci...328..636R. doi:10.1126/science.1186802. PMC 3037280. PMID 20220176.
- Lee, et al.; Jiang, Zhaoshi; Liu, Jinfeng; Haverty, Peter M.; Guan, Yinghui; Stinson, Jeremy; Yue, Peng; Zhang, Yan et al. (27 May 2010)). "The mutation spectrum revealed by paired genome sequences from a lung cancer patient". Nature 465 (7297): 473–477. Bibcode:2010Natur.465..473L. doi:10.1038/nature09004. PMID 20505728.
- Baker, Monya (15 September 2012). "Impact of impending US budget cut on science revealed". Nature.
- Pollack, Andrew (December 30, 2012). "U.S. Clears DNA Firm's Acquisition by Chinese". The New York Times. Retrieved December 31, 2012.